Price
No data yet.
Social Signal Score
Revenue
No revenue history available for this company.
Company Profile
- CEO
- William Wang
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Beta
- 0.09
- Country
- US
Financials
Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $2.20M | $-3.82M | $0.00 |
| 2024 | $3.36M | $-1.19M | $0.00 |
| 2023 | $879.0K | $399.0K | $0.00 |
Valuation
SLBThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
80+14.29%Social Signal Score
Mentions (2)
- Newsglobenewswire.com·5h ago·Negative
…an Active First Quarter as a Publicly Traded Company NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in developing innovative cellular and gene therapies, today announced that its management team rang Nasdaq bell at the Nasdaq MarketSite in Times Square, New York, to celebrate its first quarter as a publicly traded company.
View source ↗ - Newsglobenewswire.com·6d ago·Negative
…nding the Regulatory Foundation of its Platform TAIPEI, Taiwan, Aug. 27, 2026 (GLOBE NEWSWIRE) -- SL Science Holding Limited (“SL Science” or the “Company”) (NASDAQ: SLBT), a Taiwan-headquartered biomedical company specializing in innovative cellular and gene therapies, today highlighted the filing of a new Drug Master File (DMF) with the U.S. Food and Drug Administration (FDA). The DMF, filed under number 044612, covers exosomes derived from Gamma Delta T (GDT) cells. It was filed by JY BioMed …
View source ↗
Insider trading
Open-market buys and sells by SLBT officers and directors.
No open-market trades in the recent filings. All 10 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
10 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.